HCHege Christensen

Hege Christensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hege Christensen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandra Peric

    Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

    1 shared publication
  • Anders Åsberg

    Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway; Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway

    1 shared publication
  • Are Hugo Pripp

    Oslo Centre of Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway

    1 shared publication
  • Aslan Lashkarivand

    Oslo University Hospital, Oslo, Norway

    1 shared publication
  • Bjørnar Hassel

    University of Oslo and Oslo University Hospital

    1 shared publication
  • Cecilia Karlsson

    Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

    1 shared publication

Latest Publications

  • Open Access

    Clinical application of intrathecal gadobutrol for assessment of cerebrospinal fluid tracer clearance to blood

    by Per K. Eide, Espen Mariussen, Hilde Uggerud, Are H. Pripp, Aslan Lashkarivand, Bjørnar Hassel, Hege Christensen, Markus Herberg Hovd, Geir Ringstad

    BACKGROUND: Methodology for estimation of cerebrospinal fluid (CSF) tracer clearance could have wide clinical application in predicting excretion of intrathecal drugs and metabolic solutes from brain metabolism and for diagnostic workup of CSF disturbances. METHODS: The MRI contrast agent gadobutrol (Gadovist) was used as a CSF tracer and injected into the lumbar CSF. Gadobutrol is contained outside blood vessels of the CNS and is eliminated along extravascular pathways, analogous to many CNS metabolites and intrathecal drugs. Tracer enrichment was verified and assessed in CSF by MRI at the level of the cisterna magna in parallel with obtaining blood samples through 48 hours. RESULTS: In a reference patient cohort ( n = 29), both enrichment within CSF and blood coincided in time. Blood concentration profiles of gadobutrol through 48 hours varied between patients diagnosed with CSF leakage ( n = 4), idiopathic normal pressure hydrocephalus dementia ( n = 7), pineal cysts ( n = 8), and idiopathic intracranial hypertension ( n = 4). CONCLUSION: Assessment of CSF tracer clearance is clinically feasible and may provide a way to predict extravascular clearance of intrathecal drugs and endogenous metabolites from the CNS. The peak concentration in blood (at about 10 hours) was preceded by far peak tracer enhancement at MRI in extracranial lymphatic structures (at about 24 hours), as shown in previous studies, indicating a major role of the spinal canal in CSF clearance capacity. FUNDING: The work was supported by the Department of Neurosurgery, Oslo University Hospital; the Norwegian Institute for Air Research; and the University of Oslo.


  • Open Access

    Correlation of Body Weight and Composition With Hepatic Activities of Cytochrome P450 Enzymes

    by Veronica Krogstad, Alexandra Peric, Ida Robertsen, Marianne K. Kringen, Maria Vistnes, Jøran Hjelmesæth, Rune Sandbu, Line Kristin Johnson, Philip Carlo Angeles, Rasmus Jansson-Löfmark, et al.